The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

Cornelis H van Werkhoven; Susanne M Huijts; Marieke Bolkenbaas; Diederick E Grobbee; Marc J M Bonten

doi:10.1093/cid/civ686

The Impact of Age on the Efficacy of 13-valent Pneumococcal Conjugate Vaccine in Elderly

Clin Infect Dis. 2015 Dec 15;61(12):1835-8. doi: 10.1093/cid/civ686. Epub 2015 Aug 11.

Authors

Cornelis H van Werkhoven¹, Susanne M Huijts², Marieke Bolkenbaas¹, Diederick E Grobbee¹, Marc J M Bonten³

Affiliations

¹ Julius Center for Health Sciences and Primary Care.
² Julius Center for Health Sciences and Primary Care Department of Pulmonary Medicine.
³ Julius Center for Health Sciences and Primary Care Department of Medical Microbiology, University Medical Center Utrecht, The Netherlands.

PMID: 26265498
DOI: 10.1093/cid/civ686

Abstract

In a post hoc analysis of the Community-Acquired Pneumonia (CAP) immunization Trial in Adults the model-predicted 13-valent pneumococcal conjugate vaccine efficacy for preventing vaccine-type specific CAP and Invasive Pneumococcal Disease declined from 65% to 40% for subjects being 65 and 75 year olds at the time of vaccination, respectively.

Keywords: community-acquired pneumonia; immunosenescence; invasive pneumococcal disease; pneumococcal conjugate vaccine; vaccine efficacy.

Publication types

Randomized Controlled Trial

MeSH terms

Age Factors
Aged
Aged, 80 and over
Double-Blind Method
Female
Humans
Male
Pneumococcal Infections / prevention & control*
Pneumococcal Vaccines / administration & dosage*
Pneumococcal Vaccines / immunology*
Treatment Outcome

Substances

13-valent pneumococcal vaccine
Pneumococcal Vaccines